49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01956188 (ClinicalTrials.gov)	May 2014	25/9/2013	Omega 3 in LES and APS	Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome	Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome	Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo	University of Sao Paulo	NULL	Active, not recruiting	20 Years	45 Years	Female	22	N/A	Brazil
2	EUCTR2005-000706-31-IT (EUCTR)	15/09/2005	30/09/2005	A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosus	A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosus	improvement of signs and symptoms of Active Systemic Lupus Erythematosus MedDRA version: 8.1;Level: LLT;Classification code 10042945;Term: Systemic lupus erythematosus	Product Name: Epatuzumab Product Code: hLL2,IMMU-103	IMMUNOMEDICS	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	Germany;United Kingdom;Spain;Italy